NPC1L1 and metabolic dysfunction-associated steatotic liver disease: For instance, studies have demonstrated that the genetic deletion or pharmacological inhibition of NPC1L1 reduces hepatic cholesterol content and ameliorates liver steatosis in high-fat diet (HFD)-fed NAFLD mice [13,14].